Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

Characterization of CYP2B6 K262R allelic variants by quantitative allele-specific proteomics using a QconCAT standard.

Barber J, Russell MR, Rostami-Hodjegan A, Achour B.

J Pharm Biomed Anal. 2019 Oct 3;178:112901. doi: 10.1016/j.jpba.2019.112901. [Epub ahead of print]

PMID:
31610395
2.

Quantitative Translation of Microfluidic Transporter in Vitro Data to in Vivo Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease.

van der Made TK, Fedecostante M, Scotcher D, Rostami-Hodjegan A, Sastre Toraño J, Middel I, Koster AS, Gerritsen KG, Jankowski V, Jankowski J, Hoenderop JGJ, Masereeuw R, Galetin A.

Mol Pharm. 2019 Nov 4;16(11):4551-4562. doi: 10.1021/acs.molpharmaceut.9b00681. Epub 2019 Sep 27.

PMID:
31525064
3.

Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice.

El-Khateeb E, Vasilogianni AM, Alrubia S, Al-Majdoub ZM, Couto N, Howard M, Barber J, Rostami-Hodjegan A, Achour B.

Pharmacol Ther. 2019 Nov;203:107397. doi: 10.1016/j.pharmthera.2019.107397. Epub 2019 Jul 31. Review.

PMID:
31376433
4.

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children.

Brussee JM, Krekels EHJ, Calvier EAM, Palić S, Rostami-Hodjegan A, Danhof M, Barrett JS, de Wildt SN, Knibbe CAJ.

AAPS J. 2019 Jun 27;21(5):81. doi: 10.1208/s12248-019-0351-9.

5.

Toward a Consensus on Applying Quantitative Liquid Chromatography-Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper.

Prasad B, Achour B, Artursson P, Hop CECA, Lai Y, Smith PC, Barber J, Wisniewski JR, Spellman D, Uchida Y, Zientek MA, Unadkat JD, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2019 Sep;106(3):525-543. doi: 10.1002/cpt.1537. Epub 2019 Jul 26.

PMID:
31175671
6.

Come Dance With Me: Transformative Changes in the Science and Practice of Drug-Drug Interactions.

Venkatakrishnan K, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2019 Jun;105(6):1272-1278. doi: 10.1002/cpt.1433. Epub 2019 Apr 20.

PMID:
31004453
7.

Drug-Drug Interactions: Progress Over the Past Decade and Looking Ahead to the Future.

Derendorf H, von Richter O, Hermann R, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2019 Jun;105(6):1289-1291. doi: 10.1002/cpt.1410. Epub 2019 Apr 12. No abstract available.

PMID:
30977519
8.

Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics.

Melillo N, Darwich AS, Magni P, Rostami-Hodjegan A.

J Pharmacokinet Pharmacodyn. 2019 Apr;46(2):137-154. doi: 10.1007/s10928-019-09627-6. Epub 2019 Mar 23.

PMID:
30905037
9.

Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method.

Calvier EAM, Krekels EHJ, Johnson TN, Rostami-Hodjegan A, Tibboel D, Knibbe CAJ.

AAPS J. 2019 Mar 8;21(3):38. doi: 10.1208/s12248-019-0295-0.

10.

The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall.

Darwich AS, Burt HJ, Rostami-Hodjegan A.

Eur J Pharm Sci. 2019 Apr 1;131:195-207. doi: 10.1016/j.ejps.2019.02.017. Epub 2019 Feb 15.

PMID:
30776469
11.

Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients.

Al-Majdoub ZM, Al Feteisi H, Achour B, Warwood S, Neuhoff S, Rostami-Hodjegan A, Barber J.

Mol Pharm. 2019 Mar 4;16(3):1220-1233. doi: 10.1021/acs.molpharmaceut.8b01189. Epub 2019 Feb 8.

PMID:
30735053
12.
13.

What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing.

Polasek TM, Rostami-Hodjegan A, Yim DS, Jamei M, Lee H, Kimko H, Kim JK, Nguyen PTT, Darwich AS, Shin JG.

AAPS J. 2019 Jan 9;21(2):17. doi: 10.1208/s12248-018-0286-6.

PMID:
30627939
14.

Quantification of Proteins Involved in Drug Metabolism and Disposition in the Human Liver Using Label-Free Global Proteomics.

Couto N, Al-Majdoub ZM, Achour B, Wright PC, Rostami-Hodjegan A, Barber J.

Mol Pharm. 2019 Feb 4;16(2):632-647. doi: 10.1021/acs.molpharmaceut.8b00941. Epub 2019 Jan 18.

PMID:
30608694
15.

Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development.

Polasek TM, Rayner CR, Peck RW, Rowland A, Kimko H, Rostami-Hodjegan A.

Clin Pharmacol Drug Dev. 2019 May;8(4):418-425. doi: 10.1002/cpdd.638. Epub 2018 Nov 30.

PMID:
30500115
16.

Dose adjustment in orphan disease populations: the quest to fulfill the requirements of physiologically based pharmacokinetics.

Howard M, Barber J, Alizai N, Rostami-Hodjegan A.

Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1315-1330. doi: 10.1080/17425255.2018.1546288. Epub 2018 Nov 22. Review.

PMID:
30465453
17.

Response to "Determining Allele-Specific Protein Expression (ASPE) Using a Novel Quantitative Concatamer Based Proteomics Method".

Achour B, Rostami-Hodjegan A, Barber J.

J Proteome Res. 2019 Jan 4;18(1):574. doi: 10.1021/acs.jproteome.8b00871. Epub 2018 Nov 20.

PMID:
30444614
18.

Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance.

Matsuzaki T, Scotcher D, Darwich AS, Galetin A, Rostami-Hodjegan A.

J Pharmacol Exp Ther. 2019 Feb;368(2):157-168. doi: 10.1124/jpet.118.251413. Epub 2018 Nov 9. Erratum in: J Pharmacol Exp Ther. 2019 Mar;368(3):474.

PMID:
30413628
19.

GASP and FASP are Complementary for LC-MS/MS Proteomic Analysis of Drug-Metabolizing Enzymes and Transporters in Pig Liver.

Howard M, Achour B, Al-Majdoub Z, Rostami-Hodjegan A, Barber J.

Proteomics. 2018 Dec;18(24):e1800200. doi: 10.1002/pmic.201800200. Epub 2018 Nov 30.

PMID:
30371990
20.

Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory.

Calvier EAM, Nguyen TT, Johnson TN, Rostami-Hodjegan A, Tibboel D, Krekels EHJ, Knibbe CAJ.

Pharm Res. 2018 Sep 14;35(11):209. doi: 10.1007/s11095-018-2487-1.

21.

Physiologically based pharmacokinetic modelling to guide drug delivery in older people.

Chetty M, Johnson TN, Polak S, Salem F, Doki K, Rostami-Hodjegan A.

Adv Drug Deliv Rev. 2018 Oct;135:85-96. doi: 10.1016/j.addr.2018.08.013. Epub 2018 Sep 4. Review.

22.

Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.

Brussee JM, Yu H, Krekels EHJ, Palić S, Brill MJE, Barrett JS, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ.

Pharm Res. 2018 Jul 30;35(9):182. doi: 10.1007/s11095-018-2458-6.

23.

Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Standing JF, Anderson BJ, Hennig S, Holford NH, Johnston TN, Knibbe CAJ, Lonsdale DO, Rostami-Hodjegan A.

Clin Pharmacokinet. 2018 Nov;57(11):1471-1472. doi: 10.1007/s40262-018-0697-7. No abstract available.

PMID:
30027513
24.

Precision dosing in clinical medicine: present and future.

Polasek TM, Shakib S, Rostami-Hodjegan A.

Expert Rev Clin Pharmacol. 2018 Aug;11(8):743-746. doi: 10.1080/17512433.2018.1501271. Epub 2018 Jul 20. No abstract available.

PMID:
30010447
25.

Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.

Cristofoletti R, Rowland M, Lesko LJ, Blume H, Rostami-Hodjegan A, Dressman JB.

J Pharm Sci. 2018 Oct;107(10):2519-2530. doi: 10.1016/j.xphs.2018.06.013. Epub 2018 Jun 20.

PMID:
29935299
26.

First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.

Brussee JM, Yu H, Krekels EHJ, de Roos B, Brill MJE, van den Anker JN, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):374-383. doi: 10.1002/psp4.12295. Epub 2018 May 10.

27.

Identification and quantification of blood-brain barrier transporters in isolated rat brain microvessels.

Al Feteisi H, Al-Majdoub ZM, Achour B, Couto N, Rostami-Hodjegan A, Barber J.

J Neurochem. 2018 Sep;146(6):670-685. doi: 10.1111/jnc.14446. Epub 2018 Aug 1.

28.

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz.

Chetty M, Cain T, Wedagedera J, Rostami-Hodjegan A, Jamei M.

Front Pharmacol. 2018 Mar 27;9:247. doi: 10.3389/fphar.2018.00247. eCollection 2018.

29.

Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5'-Diphosphate-Glucuronosyltransferase Enzymes with Reference to Catalytic Activity.

Achour B, Dantonio A, Niosi M, Novak JJ, Al-Majdoub ZM, Goosen TC, Rostami-Hodjegan A, Barber J.

Drug Metab Dispos. 2018 Jun;46(6):805-812. doi: 10.1124/dmd.117.079475. Epub 2018 Mar 26.

PMID:
29581103
30.

Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.

Rowland A, van Dyk M, Hopkins AM, Mounzer R, Polasek TM, Rostami-Hodjegan A, Sorich MJ.

Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. doi: 10.1002/cpt.1076. Epub 2018 Apr 19.

PMID:
29574693
31.

Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice: Drug-Drug and Food-Drug Interactions.

Hermann R, Derendorf H, von Richter O, Rostami-Hodjegan A.

J Clin Pharmacol. 2018 Jun;58(6):704-716. doi: 10.1002/jcph.1088. Epub 2018 Mar 7. No abstract available.

PMID:
29513896
32.

Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.

Calvier EAM, Krekels EHJ, Yu H, Välitalo PAJ, Johnson TN, Rostami-Hodjegan A, Tibboel D, van der Graaf PH, Danhof M, Knibbe CAJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):175-185. doi: 10.1002/psp4.12273. Epub 2018 Feb 5.

33.

Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.

Doki K, Darwich AS, Achour B, Tornio A, Backman JT, Rostami-Hodjegan A.

Br J Clin Pharmacol. 2018 May;84(5):972-986. doi: 10.1111/bcp.13533. Epub 2018 Mar 6.

34.

Revisiting Principles Behind Drug Clearance and Organ Extraction.

Rostami-Hodjegan A.

Clin Pharmacol Ther. 2018 Mar;103(3):388-389. doi: 10.1002/cpt.964. Epub 2017 Dec 20.

PMID:
29266230
35.

Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition.

Abduljalil K, Johnson TN, Rostami-Hodjegan A.

Clin Pharmacokinet. 2018 Sep;57(9):1149-1171. doi: 10.1007/s40262-017-0618-1.

PMID:
29264787
36.

Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Polasek TM, Tucker GT, Sorich MJ, Wiese MD, Mohan T, Rostami-Hodjegan A, Korprasertthaworn P, Perera V, Rowland A.

Br J Clin Pharmacol. 2018 Mar;84(3):462-476. doi: 10.1111/bcp.13480. Epub 2018 Jan 11.

37.

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.

Rostami-Hodjegan A.

Clin Pharmacol Ther. 2018 Feb;103(2):224-232. doi: 10.1002/cpt.904. Epub 2017 Nov 9. Review.

38.

Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria.

Doki K, Darwich AS, Patel N, Rostami-Hodjegan A.

Eur J Pharm Sci. 2017 Nov 15;109:111-120. doi: 10.1016/j.ejps.2017.07.035. Epub 2017 Aug 1.

39.

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.

Achour B, Dantonio A, Niosi M, Novak JJ, Fallon JK, Barber J, Smith PC, Rostami-Hodjegan A, Goosen TC.

Drug Metab Dispos. 2017 Oct;45(10):1102-1112. doi: 10.1124/dmd.117.076703. Epub 2017 Aug 2.

PMID:
28768682
40.

Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes.

Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer HM, Artursson P.

Mol Pharm. 2017 Sep 5;14(9):3142-3151. doi: 10.1021/acs.molpharmaceut.7b00364. Epub 2017 Aug 16.

41.

The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.

Musther H, Harwood MD, Yang J, Turner DB, Rostami-Hodjegan A, Jamei M.

J Pharm Sci. 2017 Sep;106(9):2826-2838. doi: 10.1016/j.xphs.2017.05.003. Epub 2017 May 8.

PMID:
28495566
42.

Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical Scientist.

Kusuhara H, Obach RS, Rostami-Hodjegan A, Pang KS, Hammarlund-Udenaes M, Derendorf H, Artursson P, Huang SM, Suzuki H, Terasaki T.

J Pharm Sci. 2017 Sep;106(9):2188-2194. doi: 10.1016/j.xphs.2017.04.072. Epub 2017 May 4. No abstract available.

PMID:
28479350
43.

Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes.

Achour B, Al Feteisi H, Lanucara F, Rostami-Hodjegan A, Barber J.

Drug Metab Dispos. 2017 Jun;45(6):666-675. doi: 10.1124/dmd.116.074732. Epub 2017 Apr 3.

PMID:
28373266
44.

Systems Toxicology: Real World Applications and Opportunities.

Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A, Shah I, Wilks MF, Sturla SJ.

Chem Res Toxicol. 2017 Apr 17;30(4):870-882. doi: 10.1021/acs.chemrestox.7b00003. Epub 2017 Mar 31.

45.

Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?

Rostami-Hodjegan A, Tamai I, Pang KS.

Biopharm Drug Dispos. 2017 Mar;38(2):87-93. doi: 10.1002/bdd.2071. No abstract available.

PMID:
28317174
46.

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance.

Scotcher D, Billington S, Brown J, Jones CR, Brown CDA, Rostami-Hodjegan A, Galetin A.

Drug Metab Dispos. 2017 May;45(5):556-568. doi: 10.1124/dmd.117.075242. Epub 2017 Mar 7.

47.

Biopharmaceutics data management system for anonymised data sharing and curation: First application with orbito IMI project.

Lacy-Jones K, Hayward P, Andrews S, Gledhill I, McAllister M, Abrahamsson B, Rostami-Hodjegan A, Pepin X.

Comput Methods Programs Biomed. 2017 Mar;140:29-44. doi: 10.1016/j.cmpb.2016.11.006. Epub 2016 Nov 18.

PMID:
28254086
48.

Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.

Pade D, Jamei M, Rostami-Hodjegan A, Turner DB.

Biopharm Drug Dispos. 2017 Mar;38(2):94-114. doi: 10.1002/bdd.2072.

PMID:
28214380
49.
50.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269

Supplemental Content

Loading ...
Support Center